Abstract
* Three new drugs have been approved: golimumab (Simponi) for severe rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis; tolvaptan (Samsca) for hyponatremia associated with congestive heart failure, liver cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion; and iloperidone (Fanapt) for the treatment of schizophrenia in adults.
* Bevacizumab (Avastin), a monoclonal antibody, has been approved for a new indication-the treatment of glioblastoma multiforme, an aggressive form of brain cancer that continues to progress with conventional therapy.